Abstract | OBJECTIVES: METHODS: We performed a retrospective analysis of 76 men with Gleason sum 6 or 7 prostate cancer treated by radical prostatectomy and a separate cohort of 75 men with metastatic prostate cancer. Syndecan-1 immunoreactivity was measured in primary prostate specimens or in samples from metastatic sites and correlated with patient outcome. RESULTS:
Syndecan-1 was expressed in normal basal and secretory epithelial cells, 26% of radical prostatectomy specimens, and 35% of metastatic disease. No association was found between syndecan-1 positivity and prostate-specific antigen recurrence in the collective cohort of Gleason sum 6 and 7 cancers. However, when stratified by Gleason sum, syndecan-1 immunoreactivity (immunoreactivity score 150 or greater) was associated with a greater recurrence rate in Gleason sum 7 cancers. Expression of syndecan-1 was significantly greater in soft tissue than in bone metastasis (P = 0.048, Fisher's exact test). CONCLUSIONS:
|
Authors | David Chen, Bosede Adenekan, Lu Chen, E Darracott Vaughan, William Gerald, Ziding Feng, Beatrice S Knudsen |
Journal | Urology
(Urology)
Vol. 63
Issue 2
Pg. 402-7
(Feb 2004)
ISSN: 1527-9995 [Electronic] United States |
PMID | 14972511
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Biomarkers, Tumor
- Membrane Glycoproteins
- Neoplasm Proteins
- Proteoglycans
- SDC1 protein, human
- Syndecan-1
- Syndecans
- Prostate-Specific Antigen
|
Topics |
- Adenocarcinoma
(genetics, metabolism, pathology)
- Biomarkers, Tumor
(blood)
- Cohort Studies
- Disease-Free Survival
- Humans
- Life Tables
- Male
- Membrane Glycoproteins
(biosynthesis, genetics, physiology)
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Metastasis
- Neoplasm Proteins
(biosynthesis, blood, genetics, physiology)
- Prostate-Specific Antigen
(blood)
- Prostatic Neoplasms
(genetics, metabolism, pathology)
- Proteoglycans
(biosynthesis, genetics, physiology)
- Retrospective Studies
- Syndecan-1
- Syndecans
|